ArticleJournal of immunology (Baltimore, Md. : 1950)2009
Tumor regulatory T cells potently abrogate antitumor immunity.
Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Knowledge landscape of Treg research in breast cancer: a bibliometric and visual analysis.Frontiers in oncology · 2024Pooled it
- Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.Cancer immunology, immunotherapy : CII · 2012Trial
- Modulation of the PD-1/PD-L1 axis and tumor immunity by metals and metalloids: mechanistic insights and human health implications.Frontiers in immunology · 2026Review
- Tumor-derived small extracellular vesicles loaded with functionally active miR-34a mimic can modify the anti-tumor response in 4T1 breast cancer animal model.Cancer cell international · 2025Article
- Intranodal Injection of Immune Activator Demonstrates Antitumor Efficacy in an Adjuvant Approach.Vaccines · 2024Article
- Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Lichen Sclerosus: A Current Landscape of Autoimmune and Genetic Interplay.Diagnostics (Basel, Switzerland) · 2022Review
- Anti-proliferative and immunomodulatory potencies of cinnamon oil on Ehrlich ascites carcinoma bearing mice.Scientific reports · 2022Article
- Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance.ImmunoHorizons · 2021Article
- Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.Frontiers in cell and developmental biology · 2021Review
- Quality of CD8Science advances · 2020Article
- Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions.Journal for immunotherapy of cancer · 2020Article
- The Effects of WW2/WW3 Domains of Smurf2 Molecule on CD4+CD25+/CD4+ Proportion in Spleen of 4T1 Tumor Bearing BALB/c Mice.Iranian biomedical journal · 2020Article
- Anti-neoplastic and immunomodulatory potency of co-treatment based on bovine lactoferrin and/or muramyl dipeptide in tumor-bearing mice.Toxicology research · 2020Article
- Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.International journal of molecular sciences · 2020Review
- Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy.Nanomedicine (London, England) · 2020Article
- Review
- Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.Journal for immunotherapy of cancer · 2019Article
- Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.BMC cancer · 2019Article
- Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model.Cancer immunology, immunotherapy : CII · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Regulatory T cell (Treg) from mice bearing a breast tumor were elevated (tumor Treg). In vitro, whereas tumor Treg ability to inhibit tumor-primed CD4(+) T cell activity is comparable to Treg from naive mice (naive Treg), only tumor Treg suppress naive CD8(+) T cell activation and DC function. Neither tumor Treg nor naive Treg can suppress antitumor immunity at the effector phase of the immune response induced by adoptively transferred tumor-primed CD4(+) T cells. This is consistent with the observation that, in this model, neither tumor Treg nor naive Treg can inhibit effectors in vitro or in vivo. However, tumor Treg abrogate tumor-specific CD8(+) T cell responses in tumor-draining lymph nodes and antitumor immunity at the early stage of the immune response induced by adoptively transferred tumor-primed CD4(+) T cells. These data indicate that, in this model, tumor Treg potently abrogate tumor-specific CD8(+) T cell responses in tumor-draining lymph nodes, thereby suppressing antitumor immunity at the early stage of the immune response induced by adoptively transferred tumor-primed CD4(+) T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.